Hypertension in Pregnancy and GDM, Management Plan: Simplified

Hypertension in Pregnancy

Swaraj Hospital and Research Institute, Balangir

A Simple, Illustrated Management Plan

Based on: A Practical Manual of Diabetes in Pregnancy, Chapter 15
McCance, Maresh & Sacks (Eds.) — Wiley-Blackwell, 2010
(Chapter authors: Mathiesen, Nielsen & Damm)

1. Classifying Hypertensive Disorders

Hypertension complicates roughly 1 in 10 pregnancies generally, and is even more common in women with pre-existing (Type 1 or Type 2) diabetes or gestational diabetes. There are four main categories:

Category	Definition
Chronic hypertension	BP ≥140/90 mmHg before pregnancy or before 20 weeks' gestation, or hypertension first found during pregnancy that doesn't resolve postpartum. (In diabetic women, some centers use >135/85 or even >130/80 mmHg as the threshold.)
Gestational hypertension	BP >140/90 mmHg first detected after 20 weeks, without proteinuria. If it resolves by 12 weeks postpartum it is reclassified as transient hypertension of pregnancy; if not, it becomes chronic hypertension.
Pre-eclampsia	BP >140/90 mmHg plus proteinuria (≥1+ dipstick or ≥300 mg/24h) after 20 weeks.
Superimposed pre-eclampsia	New-onset proteinuria (or a sudden ≥15% rise in BP in women with pre-existing nephropathy, or a sudden 2–3-fold rise in proteinuria/thrombocytopenia/liver enzymes) in a woman with pre-existing hypertension or diabetic nephropathy.

All four categories are more common in diabetic than non-diabetic women. Pre-eclampsia risk with Type 1 diabetes rises steeply with kidney involvement: 6–10% with normal urine albumin, 42% with microalbuminuria, and 64% with established diabetic nephropathy.

2. First-Visit Assessment and Ongoing Monitoring

• At the first pregnancy visit, measure BP and urinary albumin excretion, and record history of hypertension, microalbuminuria, diabetic nephropathy, and current antihypertensive treatment.
• Classify the woman according to the presence of hypertension/microalbuminuria/nephropathy.
• BP should be recorded at every visit (approximately every 1–2 weeks). Home BP monitoring can be useful; 24-hour ambulatory BP monitoring generally has not proven useful in this population.
• Normotensive, normoalbuminuric women: test for proteinuria by dipstick at each visit.
• Women with microalbuminuria, hypertension, or nephropathy: follow with 24-hour urinary albumin excretion or a spot albumin-to-creatinine ratio at each visit.

3. Blood Pressure Treatment Goals

Evidence for treating mild–moderate hypertension (140–160/90–110 mmHg) in pregnancy is limited: treatment reduces progression to severe hypertension but has not been shown to change rates of pre-eclampsia, neonatal death, preterm birth, or growth restriction. Guidelines nonetheless generally recommend treatment in diabetic pregnancy given the higher background risk.

Condition	Target BP (mmHg)	Target urinary albumin
Chronic hypertension	110–139 / 65–89	—
Microalbuminuria	110–139 / 65–89	<300 mg/24h
Diabetic nephropathy	110–139 / 65–89	<300 mg/24h
Gestational hypertension	110–139 / 65–89	—
Pre-eclampsia	110–139 / 65–89	<300 mg/24h

Some centers target tighter control — below 135/85, or even below 130/80 mmHg — particularly when microalbuminuria or nephropathy is present, as strict early control has been linked to fewer preterm deliveries.

Severe hypertension (≥160/110 mmHg) always requires treatment — it carries a real risk of intracerebral hemorrhage and maternal death. When lowering severe BP, avoid overshooting into hypotension: placental blood flow autoregulation is limited, and aggressive BP-lowering can cause fetal hypoxia.

4. Choice of Antihypertensive Medication

Add medications safe in pregnancy sequentially until target BP is reached.

Methyldopa — usually first-line

• Centrally-acting alpha-agonist; the most widely used and best-studied agent in pregnancy (40+ years of use)
• Not thought to be teratogenic; no adverse effect on utero-placental or fetal hemodynamics
• Children exposed in utero showed normal intelligence/cognitive development at 7-year follow-up

Labetalol

• Non-selective beta-blocker with additional alpha-blocking activity; extensively studied and widely accepted in diabetic pregnancy
• Beta-blockers as a class: no teratogenicity reported, but long-term use may lower birthweight; IV use linked to fetal bradycardia and neonatal hypoglycemia
• Can blunt adrenergic warning symptoms of maternal hypoglycemia — watch for hypoglycemic unawareness

Calcium channel blockers (e.g. nifedipine)

• Commonly used for chronic hypertension and late-gestation pre-eclampsia; not associated with teratogenicity
• Slow-release nifedipine preferred — does not reduce uterine blood flow
• Avoid short-acting sublingual nifedipine: risk of a steep BP drop → maternal MI, fetal bradycardia/hypoxia
• Safe to combine with magnesium sulfate (used for seizure prevention in pre-eclampsia)

Diuretics, hydralazine & others

• Diuretics may be continued if already in use pre-pregnancy (especially in salt-sensitive renal hypertension), but avoid starting them late in pregnancy — may reduce placental flow
• Hydralazine: reserved for resistant severe hypertension; IV use can cause dramatic BP drops

ACE inhibitors and ARBs are contraindicated in pregnancy — associated with congenital malformations (cardiovascular/CNS), fetal/neonatal renal failure, and oligohydramnios. Switch to a pregnancy-safe agent when planning pregnancy or as soon as pregnancy is confirmed.

Statins are contraindicated in pregnancy due to possible effects on fetal brain and nerve development.

5. Aspirin for Pre-eclampsia Prevention

• Low-dose aspirin started from around 12 weeks' gestation may reduce pre-eclampsia risk in high-risk women (including diabetic women).
• Use in the first trimester (during organogenesis) is debated because of a possible small increase in malformation risk — decide on an individual risk–benefit basis.
• A woman already taking aspirin for cardiovascular risk reduction may reasonably continue it through organogenesis.

6. Antihypertensives During Breastfeeding

• Methyldopa: low transfer into breast milk; generally considered safe.
• Labetalol and propranolol: low milk concentrations; considered acceptable.
• Atenolol and metoprolol: concentrate more in breast milk — may affect the infant; use with caution.
• Captopril and enalapril: excreted in only insignificant amounts — deemed compatible with breastfeeding by the American Academy of Pediatrics. Data on other ACE-Is/ARBs are insufficient.
• Diuretics: low, safe milk concentrations, but can meaningfully reduce milk supply.

7. Why Early, Strict Control Matters

The manual's case history illustrates the point well: a woman with Type 1 diabetes and diabetic nephropathy had two pregnancies. In the first, a conservative antihypertensive strategy was used; she progressed to severe pre-eclampsia and delivered at 32 weeks (birthweight 1800 g). In her second pregnancy, an early and aggressive antihypertensive strategy (maximal methyldopa plus labetalol from early gestation) kept her BP controlled despite ongoing heavy proteinuria; she reached 36 weeks before a planned delivery for rising creatinine (birthweight 2584 g).

Take-home point: in women with diabetic nephropathy or microalbuminuria, early and strict antihypertensive treatment (rather than waiting for BP to rise substantially) is associated with better pregnancy outcomes and fewer very-preterm deliveries.

Summary Flow

This is a simplified educational summary derived from A Practical Manual of Diabetes in Pregnancy (McCance, Maresh & Sacks, Wiley-Blackwell, 2010), Chapter 15 (Mathiesen, Nielsen & Damm), and is not a substitute for local clinical guidelines or individualized clinical judgment.

Gestational Diabetes Mallitus (GDM) Management Summary

Gestational Diabetes Mellitus

A Simple, Illustrated Management Plan

Swaraj Hospital and Research Institute, Balangir

1. Diagnosis

Diagnosed by an oral glucose tolerance test (OGTT), typically performed at 24–28 weeks of gestation (earlier if there is a prior history of GDM or other risk factors).

Diagnostic thresholds vary by protocol used locally (e.g. WHO 75-g 2-hour test vs ADA/Carpenter–Coustan 100-g 3-hour test). Follow whichever criteria are used in your unit, since the source manual predates the now widely adopted IADPSG one-step criteria.

Once diagnosed, refer promptly to a joint diabetes–obstetric antenatal clinic.

2. Initial Assessment

• Confirm gestational age accurately.
• Baseline weight/BMI, blood pressure, urinalysis.
• Assess risk factors: obesity, previous GDM, previous macrosomic baby, family history of diabetes, ethnicity.
• Educate about self-monitoring of blood glucose (SMBG), diet, and exercise.
• Involve a multidisciplinary team: obstetrician, diabetes physician, diabetes specialist nurse/midwife, and dietitian.

3. First-Line Treatment: Diet and Exercise

Diet and lifestyle change are first-line therapy for essentially all women with GDM.

Dietary principles

• Favor low glycemic index (GI) carbohydrates rather than strict restriction
• Avoid severe caloric restriction (<1200 kcal/day) — risks ketonemia
• Overweight/obese women: moderate restriction (~25 kcal/kg/day)
• Refer to a dietitian for individualized, culturally appropriate advice

Exercise

• Regular moderate activity, e.g. walking 20 min once or twice daily
• Best done after meals to blunt postprandial glucose rise
• Combined with diet, reduces need for medication

About 85% of women with GDM achieve adequate control with diet and exercise alone; roughly 15% need additional pharmacological therapy.

4. Glucose Monitoring and Targets

Home capillary blood glucose monitoring (fasting and post-meal) is standard once GDM is diagnosed.

Timing	Target
Fasting	3.5–5.9 mmol/L (63–106 mg/dL)
1-hour postprandial	< 7.8 mmol/L (140 mg/dL)
2-hour postprandial	< 6.7 mmol/L (120 mg/dL)

Evidence suggests postprandial monitoring/targets give better perinatal outcomes (lower birthweight, fewer large-for-gestational-age infants) than preprandial monitoring alone, though at the cost of somewhat higher insulin requirements when insulin is used.

Serial ultrasound assessment of fetal growth (e.g. abdominal circumference) can help guide the threshold for starting pharmacological treatment, particularly if macrosomia is suspected.

5. Escalation to Pharmacological Therapy

If glycemic targets are not met with diet and exercise alone, options include:

Insulin

• Regarded as the traditional standard of care
• Regimen (basal, prandial, or combination) individualized to the hyperglycemia pattern
• Requirements typically increase as pregnancy advances due to rising insulin resistance

Metformin

• Effective alternative to insulin; no hypoglycemia or weight gain
• Crosses the placenta freely but has not been shown to be teratogenic
• MiG trial: outcomes broadly comparable to insulin, but ~46% needed supplemental insulin; preterm birth slightly more common
• Favorable choice for overweight/obese women given weight profile and ease of use

Glyburide (Glibenclamide)

• Short-acting sulfonylurea; minimal placental transfer
• Effective in most women, but 16–21% eventually need insulin ("glyburide failure")
• Failure predictors: higher glucose challenge result, diagnosis before 25 weeks, older maternal age, multiparity, higher pretreatment fasting glucose
• Not universally available/licensed for this indication — check local practice

Choice between insulin, metformin, and glyburide should follow local guidelines, patient preference, and contraindications (e.g. metformin avoided in renal impairment).

6. Fetal Surveillance

• Serial growth ultrasound to monitor for macrosomia or growth restriction
• Increased surveillance if glycemic control is poor, macrosomia is suspected, or other risk factors are present
• Standard antenatal fetal well-being assessments otherwise apply

7. Timing and Mode of Delivery

• Diet-controlled GDM, no other complications: manage like the general obstetric population (no routine early delivery).
• Insulin-requiring GDM (or suspected macrosomia): consider elective delivery at 38–39 weeks — reduces shoulder dystocia risk without raising cesarean rates.

Individualize based on: glycemic control, estimated fetal weight/macrosomia, fetal growth restriction, maternal preference and obstetric history.

Mode of delivery: vaginal delivery is preferred where appropriate. Cesarean rates are generally higher in GDM pregnancies, partly related to maternal obesity and practice patterns rather than GDM itself.

8. Intrapartum Glycemic Management

Goal: avoid maternal hyperglycemia to reduce risk of fetal acidemia and neonatal hypoglycemia.

GDM Type	Monitoring	Target
Diet-controlled	Every 1–2 hours in established labor	< 7 mmol/L (126 mg/dL); start insulin/dextrose infusion if not met
Insulin-requiring	Hourly, IV dextrose/insulin infusion	4–7 mmol/L (72–126 mg/dL)

9. Postpartum and Neonatal Care

• Encourage early skin-to-skin contact and breastfeeding within the first hour
• Monitor neonate for hypoglycemia, especially if maternal control was suboptimal or medications were used
• Most infants do not require routine NICU admission unless there are specific concerns
• Insulin/medications for GDM are usually stopped immediately after delivery as insulin resistance resolves rapidly

10. Postpartum Follow-up (Maternal)

• Offer a 75-g OGTT at ~6 weeks postpartum to reclassify glucose tolerance
• Advise on weight management, healthy diet, and continued physical activity — reduces future risk of Type 2 diabetes
• Annual screening for diabetes with the primary care physician
• Contraception planning and repeat glucose testing before any future pregnancy (recurrence of GDM is common)
• Breastfeeding should be encouraged; no contraindications related to GDM itself

Summary Flow

This is a simplified educational summary from Swaraj Hospital and Research Institute, Bolangir and is not a substitute for local clinical guidelines or individualized clinical judgment.